MacroGenics Inc
NASDAQ:MGNX

Watchlist Manager
MacroGenics Inc Logo
MacroGenics Inc
NASDAQ:MGNX
Watchlist
Price: 1.37 USD -0.72% Market Closed
Market Cap: 86.7m USD

MacroGenics Inc
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

MacroGenics Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
MacroGenics Inc
NASDAQ:MGNX
Income from Continuing Operations
-$75.9m
CAGR 3-Years
26%
CAGR 5-Years
14%
CAGR 10-Years
-22%
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$2.4B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$8.1B
CAGR 3-Years
35%
CAGR 5-Years
46%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

MacroGenics Inc
Glance View

Market Cap
86.7m USD
Industry
Biotechnology

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 427 full-time employees. The company went IPO on 2013-10-10. The company is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. The company is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

MGNX Intrinsic Value
1.87 USD
Undervaluation 27%
Intrinsic Value
Price

See Also

What is MacroGenics Inc's Income from Continuing Operations?
Income from Continuing Operations
-75.9m USD

Based on the financial report for Sep 30, 2025, MacroGenics Inc's Income from Continuing Operations amounts to -75.9m USD.

What is MacroGenics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-22%

Over the last year, the Income from Continuing Operations growth was 22%. The average annual Income from Continuing Operations growth rates for MacroGenics Inc have been 26% over the past three years , 14% over the past five years , and -22% over the past ten years .

Back to Top